Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is rated a consensus buy by all eleven analysts, with a median price target of $19, signaling a 79.92% upside potential. Raymond James initiated coverage with a ‘Strong Buy’ rating and a $25 target, citing promising Phase 1/2 trial results for LX2006 gene therapy for Friedreich’s Ataxia. Cantor Fitzgerald reaffirmed an ‘Overweight’ rating with a $19 target, emphasizing potential in the PKP2-ACM program.

Scholar Rock (SRRK) shares surged 24% as Raymond James predicts momentum in 2026 with LX2020 gene therapy data and $805.3 million revenue projection for LX2006 by FY32. Lexeo is a NYC-based genetic medicine company with programs like LX2006 and LX2021. Consider AI stocks for higher upside potential and lower risk.

Read more at Yahoo Finance: Wall Street Rallies Behind Lexeo Therapeutics (LXEO)’s Gene Therapy Pipeline